Skip to main content

NASDAQ:PROG - Progenity Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 205.68 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.29
▲ +0.03 (1.33%)
1 month | 3 months | 12 months
Get New Progenity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PROG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PROG

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$7.00
▲ +205.68% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Progenity in the last 3 months. The average price target is $7.00, with a high forecast of $12.00 and a low forecast of $2.00. The average price target represents a 205.68% upside from the last price of $2.29.

Buy

The current consensus among 5 polled investment analysts is to buy stock in Progenity.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
8/21/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
11/19/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
2/17/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/18/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
5/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2021Wells Fargo & CompanyLower Price TargetUnderweight$4.00 ➝ $2.00High
i
5/14/2021Raymond JamesLower Price TargetOutperform$10.00 ➝ $7.00High
i
5/14/2021Robert W. BairdLower Price TargetOutperform$6.00 ➝ $4.00Medium
i
3/21/2021Robert W. BairdReiterated RatingBuy$6.00Low
i
2/8/2021Wells Fargo & CompanyDowngradeOverweight ➝ Underweight$5.00High
i
1/14/2021Piper SandlerLower Price TargetOverweight$15.00 ➝ $10.00High
i
11/10/2020Raymond JamesLower Price TargetOutperform$15.00 ➝ $10.00High
i
Rating by Andrew Cooper at Raymond James
11/10/2020Piper SandlerLower Price TargetAverage ➝ Overweight$17.00 ➝ $15.00High
i
Rating by Steven Mah at Piper Sandler
10/23/2020BTIG ResearchInitiated CoverageBuy$12.00Low
i
8/19/2020Raymond JamesReiterated RatingBuyHigh
i
Rating by Andrew Cooper at Raymond James
7/14/2020Piper SandlerInitiated CoverageOverweight$17.00High
i
7/14/2020Robert W. BairdInitiated CoverageOutperform$12.00Medium
i
7/14/2020Raymond JamesInitiated CoverageOutperform$15.00High
i
7/14/2020Wells Fargo & CompanyInitiated CoverageOverweight$11.00High
i
(Data available from 5/18/2016 forward)
Progenity logo
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $2.29
$2.22
$2.33

50 Day Range

MA: $3.45
$2.35
$4.94

52 Week Range

Now: $2.29
$2.20
$15.92

Volume

6,764 shs

Average Volume

507,889 shs

Market Capitalization

$138.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Progenity?

The following Wall Street sell-side analysts have issued reports on Progenity in the last year: BTIG Research, Piper Sandler, Raymond James, Robert W. Baird, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for PROG.

What is the current price target for Progenity?

5 Wall Street analysts have set twelve-month price targets for Progenity in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 209.7%. BTIG Research has the highest price target set, predicting PROG will reach $12.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $2.00 for Progenity in the next year.
View the latest price targets for PROG.

What is the current consensus analyst rating for Progenity?

Progenity currently has 1 sell rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PROG will outperform the market and that investors should add to their positions of Progenity.
View the latest ratings for PROG.

What other companies compete with Progenity?

How do I contact Progenity's investor relations team?

Progenity's physical mailing address is 4330 LA JOLLA VILLAGE DRIVE SUITE 200, SAN DIEGO CA, 92122. The company's listed phone number is 855-293-2639 and its investor relations email address is [email protected] The official website for Progenity is www.progenity.com.